WO2004083373A3 - Anticorps - Google Patents

Anticorps Download PDF

Info

Publication number
WO2004083373A3
WO2004083373A3 PCT/GB2004/001239 GB2004001239W WO2004083373A3 WO 2004083373 A3 WO2004083373 A3 WO 2004083373A3 GB 2004001239 W GB2004001239 W GB 2004001239W WO 2004083373 A3 WO2004083373 A3 WO 2004083373A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoprotein
syncytial virus
respiraotry
antibody against
region
Prior art date
Application number
PCT/GB2004/001239
Other languages
English (en)
Other versions
WO2004083373A2 (fr
Inventor
Geoffrey Toms
Edward Routledge
Chantana Mekseepralard
Original Assignee
Univ Newcastle
Geoffrey Toms
Edward Routledge
Chantana Mekseepralard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle, Geoffrey Toms, Edward Routledge, Chantana Mekseepralard filed Critical Univ Newcastle
Publication of WO2004083373A2 publication Critical patent/WO2004083373A2/fr
Publication of WO2004083373A3 publication Critical patent/WO2004083373A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un anticorps ou un dérivé fonctionnel de celui-ci luttant contre la glycoprotéine G du virus respiratoire syncytial (VRS). Cet anticorps présente une région variable comprenant un premier domaine d'une région VL et un second domaine d'une région VH. La présente invention concerne également des molécules d'ADN codant un tel anticorps, ainsi que des cellules transformées avec de telles molécules d'ADN.
PCT/GB2004/001239 2003-03-22 2004-03-22 Anticorps WO2004083373A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0306618.0 2003-03-22
GB0306618A GB0306618D0 (en) 2003-03-22 2003-03-22 Antibody

Publications (2)

Publication Number Publication Date
WO2004083373A2 WO2004083373A2 (fr) 2004-09-30
WO2004083373A3 true WO2004083373A3 (fr) 2004-11-04

Family

ID=9955313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001239 WO2004083373A2 (fr) 2003-03-22 2004-03-22 Anticorps

Country Status (2)

Country Link
GB (1) GB0306618D0 (fr)
WO (1) WO2004083373A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134747A2 (fr) 2007-03-06 2009-12-23 Symphogen A/S Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
US8138313B2 (en) * 2007-06-15 2012-03-20 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Treatment of tumors using specific anti-L1 antibody
US20100291108A1 (en) * 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
CA3089717A1 (fr) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Constructions d'anticorps d'acide nucleique destinees a etre utilisees contre le virus respiratoire syncytial

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010846A1 (fr) * 1995-09-18 1997-03-27 Intracel Corporation Anticorps monoclonaux neutralisants diriges contre le virus syncytial respiratoire
US5686070A (en) * 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
EP0866131A2 (fr) * 1997-03-21 1998-09-23 Sankyo Company Limited Anticorps humanisé contre l'antigène humain Fas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686070A (en) * 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
WO1997010846A1 (fr) * 1995-09-18 1997-03-27 Intracel Corporation Anticorps monoclonaux neutralisants diriges contre le virus syncytial respiratoire
EP0866131A2 (fr) * 1997-03-21 1998-09-23 Sankyo Company Limited Anticorps humanisé contre l'antigène humain Fas

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKERLIND-STOPNER B ET AL: "A SUBGROUP-SPECIFIC ANTIGENIC SITE IN THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS FORMS A DISULFIDE-BONDED LOOP", JOURNAL OF VIROLOGY, vol. 64, no. 10, 1990, pages 5143 - 5148, XP008034920, ISSN: 0022-538X *
BASTIEN N ET AL: "Protective Immune Responses Induced by the Immunization of Mice with a Recombinant Bacteriophage Displaying an Epitope of the Human Respiratory Syncytial Virus", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 234, no. 1, 21 July 1997 (1997-07-21), pages 118 - 122, XP004460112, ISSN: 0042-6822 *
CORBEIL S ET AL: "Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 6, 1 April 1996 (1996-04-01), pages 521 - 525, XP004057281, ISSN: 0264-410X *
CROWE JAMES E JR ET AL: "Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 1, no. 6, 1994, pages 701 - 706, XP008034919, ISSN: 1071-412X *
DATABASE EMBL 15 April 1998 (1998-04-15), KIM KJ, ET AL: "Anti IL-8 antibody 6G4.2.5 light chain variable region DNA sequence", XP002294735, retrieved from EBI Database accession no. AAV03224 *
DATABASE EMBL 18 January 1999 (1999-01-18), SERIZAWA N, ET AL: "Anti-human Fas humanised antibody CH11 VL-RF light chain cDNA", XP002294734, retrieved from EBI Database accession no. AAV61362 *
DATABASE EMBL 5 November 2003 (2003-11-05), LIANG Z., ET AL: "Mus musculus cell-line 1EA11 ANA immunoglobulin kappa light chain gene, partial cds", XP002294736, retrieved from EBI Database accession no. AY436864 *
MORGAN L A ET AL: "STRAIN VARIATION OF RESPIRATORY SYNCYTIAL VIRUS", JOURNAL OF GENERAL VIROLOGY, vol. 68, no. 11, 1987, pages 2781 - 2788, XP008034788, ISSN: 0022-1317 *
TRUDEL M ET AL: "PROTECTION OF BALB/C MICE FROM RESPIRATORY SYNCYTIAL VIRUS INFECTION BY IMMUNIZATION WITH A SYNTHETIC PEPTIDE DERIVED FROM THEG GLYCOPROTEIN", VIROLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 185, 1 December 1991 (1991-12-01), pages 749 - 757, XP002062551, ISSN: 0042-6822 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Also Published As

Publication number Publication date
GB0306618D0 (en) 2003-04-30
WO2004083373A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2006050280A3 (fr) Anticorps et antigenes anti-virus respiratoire syncytial et leurs utilisations
WO2007051164A8 (fr) Modulateurs du recepteur de type toll 3, et leurs procedes et utilisations
WO2006105062A3 (fr) Régions fc d'anticorps altérées et utilisations de celles-ci
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
EP2578600A3 (fr) Molécules à liaison spécifiques RSV et leur moyen de fabrication
WO2006047671A3 (fr) 4-aminotetracyclines et procedes d'utilisation
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2004106380A3 (fr) Molecules humaines de liaison a cd3 anti-humain
WO2003072803A3 (fr) Nanostructures contenant des unites d'assemblage d'anticorps
WO2007044763A3 (fr) Systeme et procede permettant la detection de transactions frauduleuses
WO2004029207A3 (fr) Variants fc optimises et methodes destinees a leur generation
WO2006034292A3 (fr) Anticorps dirige contre le virus respiratoire syncytial et procedes de production de vaccins associes
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
WO2004074455A3 (fr) Variants de la region fc
WO2003050202A8 (fr) Procede pour façonner un composite
WO2003093269A3 (fr) Pyrazolopyrimidine-4-one substituee
WO2008079995A3 (fr) Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps
WO2001047959A3 (fr) Molecules d'acides nucleiques isoles codant pour des antigenes associes au cancers, ces antigenes et leur utilisation
WO2006086669A3 (fr) Acides nucleiques regules par des aptameres et leurs utilisations
WO2002014485A3 (fr) Nouveau gene kallikreine
WO2005076696A3 (fr) Derives de pneumolysine
DE602004025108D1 (de) Marmorierter bouillon-, sud-, suppen-, saucen- oder würzwürfel und dessen herstellungsmethode
WO2004083373A3 (fr) Anticorps
WO2004110771A3 (fr) Elements de securite et attributs de securite a effets chromatiques
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase